Cargando…
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer
CDC42 family GTPases (RHOJ, RHOQ, CDC42) are upregulated but rarely mutated in cancer and control both the ability of tumor cells to invade surrounding tissues and the ability of endothelial cells to vascularize tumors. Here, we use computer-aided drug design to discover a chemical entity (ARN22089)...
Autores principales: | Jahid, Sohail, Ortega, Jose A., Vuong, Linh M., Acquistapace, Isabella Maria, Hachey, Stephanie J., Flesher, Jessica L., La Serra, Maria Antonietta, Brindani, Nicoletta, La Sala, Giuseppina, Manigrasso, Jacopo, Arencibia, Jose M., Bertozzi, Sine Mandrup, Summa, Maria, Bertorelli, Rosalia, Armirotti, Andrea, Jin, Rongsheng, Liu, Zheng, Chen, Chi-Fen, Edwards, Robert, Hughes, Christopher C.W., De Vivo, Marco, Ganesan, Anand K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127750/ https://www.ncbi.nlm.nih.gov/pubmed/35385746 http://dx.doi.org/10.1016/j.celrep.2022.110641 |
Ejemplares similares
-
Design, Synthesis, In Vitro and In Vivo Characterization of
CDC42 GTPase Interaction Inhibitors
for the Treatment of Cancer
por: Brindani, Nicoletta, et al.
Publicado: (2023) -
Design, Synthesis,
Dynamic Docking, Biochemical Characterization,
and in Vivo Pharmacokinetics Studies of Novel Topoisomerase
II Poisons with Promising Antiproliferative Activity
por: Arencibia, Jose M., et al.
Publicado: (2020) -
Novel, Potent,
and Druglike Tetrahydroquinazoline
Inhibitor That Is Highly Selective for Human Topoisomerase II α
over β
por: Ortega, Jose Antonio, et al.
Publicado: (2020) -
Innovative Non-PrP-Targeted
Drug Strategy Designed
to Enhance Prion Clearance
por: Colini Baldeschi, Arianna, et al.
Publicado: (2022) -
Alchemical Free Energy Calculations to Investigate
Protein–Protein Interactions: the Case of the CDC42/PAK1 Complex
por: La Serra, Maria Antonietta, et al.
Publicado: (2022)